AR075058A1 - Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion - Google Patents
Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacionInfo
- Publication number
- AR075058A1 AR075058A1 ARP100100462A ARP100100462A AR075058A1 AR 075058 A1 AR075058 A1 AR 075058A1 AR P100100462 A ARP100100462 A AR P100100462A AR P100100462 A ARP100100462 A AR P100100462A AR 075058 A1 AR075058 A1 AR 075058A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenylephrine
- loratadine
- film
- layer formed
- pharmaceutical composition
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 4
- 229960001802 phenylephrine Drugs 0.000 abstract 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract 3
- 229960003088 loratadine Drugs 0.000 abstract 3
- 239000002998 adhesive polymer Substances 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- 238000013265 extended release Methods 0.000 abstract 2
- 206010052140 Eye pruritus Diseases 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una cápsula de liberacion prolongada que contiene de 2.5 mg hasta 20.0 mg de loratadina y de 10.0 mg hasta 180 mg de fenilefrina, o sus sales farmacéuticamente aceptables, caracterizada porque comprende microesferas con la siguiente configuracion: a) un nucleo inerte recubierto con una primera película o capa formada por el 30 - 70 % de la dosis de fenilefrina y al menos un polímero adhesivo; b) una segunda película o capa formada por al menos un polímero retardante; y c) una tercera película o capa formada por e]. 30 - 70% de la dosis de fenilefrina, loratadina y al menos un polímero adhesivo; en donde fenilefrina presenta liberacion modificada y loratadina presenta liberacion inmediata. Reivindicacion 4: El uso de la cápsula de liberacion prolongada de la reivindicacion 1 para la preparacion de un medicamento indicado en el tratamiento de rinitis alérgica, congestion nasal y prurito oculo nasal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2009001925A MX2009001925A (es) | 2009-02-20 | 2009-02-20 | Composicion farmaceutica oral para uso en enfermedades respiratorias. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075058A1 true AR075058A1 (es) | 2011-03-09 |
Family
ID=42633450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100462A AR075058A1 (es) | 2009-02-20 | 2010-02-17 | Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120064155A1 (es) |
| AR (1) | AR075058A1 (es) |
| CO (1) | CO6410284A2 (es) |
| CR (1) | CR20110436A (es) |
| DO (1) | DOP2011000267A (es) |
| HN (1) | HN2011002258A (es) |
| MX (1) | MX2009001925A (es) |
| PE (1) | PE20120173A1 (es) |
| WO (1) | WO2010094996A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015317469B2 (en) | 2014-09-19 | 2018-03-15 | The Procter & Gamble Company | Pulsed release phenylephrine dosage forms |
| MX391125B (es) * | 2017-01-26 | 2025-03-21 | Laboratorios Liomont S A De C V | Composicion farmaceutica de loratadina, fenilefrina, paracetamol y amantadina para su administracion oral, para el tratamiento de alopatias relacionadas a un resfriado comun. |
| US10278930B2 (en) | 2017-03-16 | 2019-05-07 | The Procter & Gamble Company | Method for relieving sinus congestion |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255968B (it) * | 1992-11-27 | 1995-11-17 | Composizioni farmaceutiche contenenti acido ursodesossicolico | |
| US20050152967A1 (en) * | 2003-03-28 | 2005-07-14 | Pfab, Lp | Dynamic variable release |
| KR20090015103A (ko) * | 2006-06-01 | 2009-02-11 | 쉐링 코포레이션 | 페닐에프린 펄스 방출 제형 및 약제학적 조성물 |
| CL2007001584A1 (es) * | 2006-06-01 | 2008-01-25 | Msd Consumer Care Inc | Composicion farmaceutica que comprende: un nucleo con fenilefrina en forma de liberacion inmediata y una capa erosionable que comprende fenilefrina y una matriz de liberacion sostenida; util para tratar los sintomas del resfriado, influenza, alergias o rinitis no alergicas. |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
-
2009
- 2009-02-20 MX MX2009001925A patent/MX2009001925A/es active IP Right Grant
- 2009-10-01 US US13/202,743 patent/US20120064155A1/en not_active Abandoned
- 2009-10-01 WO PCT/IB2009/007023 patent/WO2010094996A1/es not_active Ceased
- 2009-10-01 PE PE2011001495A patent/PE20120173A1/es active IP Right Grant
-
2010
- 2010-02-17 AR ARP100100462A patent/AR075058A1/es not_active Application Discontinuation
-
2011
- 2011-08-16 CR CR20110436A patent/CR20110436A/es unknown
- 2011-08-19 CO CO11105852A patent/CO6410284A2/es not_active Application Discontinuation
- 2011-08-19 DO DO2011000267A patent/DOP2011000267A/es unknown
- 2011-08-19 HN HN2011002258A patent/HN2011002258A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120064155A1 (en) | 2012-03-15 |
| MX2009001925A (es) | 2010-08-20 |
| WO2010094996A1 (es) | 2010-08-26 |
| CR20110436A (es) | 2011-10-24 |
| DOP2011000267A (es) | 2011-12-31 |
| CO6410284A2 (es) | 2012-03-30 |
| PE20120173A1 (es) | 2012-03-24 |
| HN2011002258A (es) | 2014-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011961A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
| AR082167A1 (es) | Formas de dosificacion gastrorretentivas | |
| CO6300931A2 (es) | Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos | |
| BR112012008317A2 (pt) | produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal | |
| AR066420A1 (es) | Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso. | |
| MX386380B (es) | Forma de dosis de disolución rápida de vacuna oral que usa almidón. | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| NI201300054A (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| CO6140021A2 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
| JP2013541583A5 (es) | ||
| AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
| DE602008006243D1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| AR066924A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| ECSP099602A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas | |
| AR075058A1 (es) | Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion | |
| CL2013003176A1 (es) | Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |